Pathomechanistic paradigms in autoimmune blistering diseases

Pamela Aubert, Kim B. Yancey

Research output: Contribution to journalArticle

Abstract

Autoimmune blistering diseases are classified by clinical, histological, and immunopathologic findings. As demonstrated by traditional immunofluorescence microscopy studies of patient skin and serum samples, these diseases develop as a consequence of loss of immunologic tolerance to self (i.e. skin) and are mediated by disease-specific autoantibodies. Subsequently, such autoantibodies were used to identify and characterize disease-specific target autoantigens in skin which interestingly are now recognized to be important structural proteins that mediate cell:cell or cell:matrix adhesion. In parallel with these advances, additional studies showed that patient autoantibodies are pathogenic in in vivo passive transfer animal models. Recent advances have explored pathomechanisms of disease and shown that autoantibodies disrupt cell:cell and cell:matrix adhesion by direct effects as well as secondary downstream events. Elucidation of variables that initiate loss of tolerance to skin, production of pathogenic (i.e. disease-causing) autoantibodies, and downstream disease pathomechanisms hold the potential to identify new target directed therapies that control these life threatening disorders without associated generalized immunosuppression, secondary infections, or drug toxicities.

Original languageEnglish (US)
JournalDrug Discovery Today: Disease Mechanisms
Volume10
Issue number3-4
DOIs
StatePublished - Dec 2013

Fingerprint

Autoantibodies
Autoimmune Diseases
Cell-Matrix Junctions
Skin
Autoantigens
Drug-Related Side Effects and Adverse Reactions
Coinfection
Fluorescence Microscopy
Skin Diseases
Immunosuppression
Animal Models
Serum
Proteins
Therapeutics

ASJC Scopus subject areas

  • Drug Discovery
  • Molecular Medicine

Cite this

Pathomechanistic paradigms in autoimmune blistering diseases. / Aubert, Pamela; Yancey, Kim B.

In: Drug Discovery Today: Disease Mechanisms, Vol. 10, No. 3-4, 12.2013.

Research output: Contribution to journalArticle

@article{635ba525b562436b9bd1cb6c4362d46b,
title = "Pathomechanistic paradigms in autoimmune blistering diseases",
abstract = "Autoimmune blistering diseases are classified by clinical, histological, and immunopathologic findings. As demonstrated by traditional immunofluorescence microscopy studies of patient skin and serum samples, these diseases develop as a consequence of loss of immunologic tolerance to self (i.e. skin) and are mediated by disease-specific autoantibodies. Subsequently, such autoantibodies were used to identify and characterize disease-specific target autoantigens in skin which interestingly are now recognized to be important structural proteins that mediate cell:cell or cell:matrix adhesion. In parallel with these advances, additional studies showed that patient autoantibodies are pathogenic in in vivo passive transfer animal models. Recent advances have explored pathomechanisms of disease and shown that autoantibodies disrupt cell:cell and cell:matrix adhesion by direct effects as well as secondary downstream events. Elucidation of variables that initiate loss of tolerance to skin, production of pathogenic (i.e. disease-causing) autoantibodies, and downstream disease pathomechanisms hold the potential to identify new target directed therapies that control these life threatening disorders without associated generalized immunosuppression, secondary infections, or drug toxicities.",
author = "Pamela Aubert and Yancey, {Kim B.}",
year = "2013",
month = "12",
doi = "10.1016/j.ddmec.2013.06.004",
language = "English (US)",
volume = "10",
journal = "Drug Discovery Today: Disease Mechanisms",
issn = "1740-6765",
publisher = "Elsevier Limited",
number = "3-4",

}

TY - JOUR

T1 - Pathomechanistic paradigms in autoimmune blistering diseases

AU - Aubert, Pamela

AU - Yancey, Kim B.

PY - 2013/12

Y1 - 2013/12

N2 - Autoimmune blistering diseases are classified by clinical, histological, and immunopathologic findings. As demonstrated by traditional immunofluorescence microscopy studies of patient skin and serum samples, these diseases develop as a consequence of loss of immunologic tolerance to self (i.e. skin) and are mediated by disease-specific autoantibodies. Subsequently, such autoantibodies were used to identify and characterize disease-specific target autoantigens in skin which interestingly are now recognized to be important structural proteins that mediate cell:cell or cell:matrix adhesion. In parallel with these advances, additional studies showed that patient autoantibodies are pathogenic in in vivo passive transfer animal models. Recent advances have explored pathomechanisms of disease and shown that autoantibodies disrupt cell:cell and cell:matrix adhesion by direct effects as well as secondary downstream events. Elucidation of variables that initiate loss of tolerance to skin, production of pathogenic (i.e. disease-causing) autoantibodies, and downstream disease pathomechanisms hold the potential to identify new target directed therapies that control these life threatening disorders without associated generalized immunosuppression, secondary infections, or drug toxicities.

AB - Autoimmune blistering diseases are classified by clinical, histological, and immunopathologic findings. As demonstrated by traditional immunofluorescence microscopy studies of patient skin and serum samples, these diseases develop as a consequence of loss of immunologic tolerance to self (i.e. skin) and are mediated by disease-specific autoantibodies. Subsequently, such autoantibodies were used to identify and characterize disease-specific target autoantigens in skin which interestingly are now recognized to be important structural proteins that mediate cell:cell or cell:matrix adhesion. In parallel with these advances, additional studies showed that patient autoantibodies are pathogenic in in vivo passive transfer animal models. Recent advances have explored pathomechanisms of disease and shown that autoantibodies disrupt cell:cell and cell:matrix adhesion by direct effects as well as secondary downstream events. Elucidation of variables that initiate loss of tolerance to skin, production of pathogenic (i.e. disease-causing) autoantibodies, and downstream disease pathomechanisms hold the potential to identify new target directed therapies that control these life threatening disorders without associated generalized immunosuppression, secondary infections, or drug toxicities.

UR - http://www.scopus.com/inward/record.url?scp=84886092317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886092317&partnerID=8YFLogxK

U2 - 10.1016/j.ddmec.2013.06.004

DO - 10.1016/j.ddmec.2013.06.004

M3 - Article

AN - SCOPUS:84886092317

VL - 10

JO - Drug Discovery Today: Disease Mechanisms

JF - Drug Discovery Today: Disease Mechanisms

SN - 1740-6765

IS - 3-4

ER -